$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Actuate Therapeutics, Inc. Common stock (ACTU)ACTU

Actuate Therapeutics, Inc. Common stock

$9.02

Delayed price

Profit since last BUY-2.28%

Consider higher Upturn Star rating

BUY since 12 days

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/12/2024: ACTU (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -2.28%	Upturn Advisory Performance 1	Avg. Invested days: 12
Profits based on simulation	Stock Returns Performance 1	Last Close 11/12/2024

Type: Stock	Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -2.28%	Avg. Invested days: 12
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/12/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 152.89M USD
Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -1.85
Volume (30-day avg) 47219	Beta -
52 Weeks Range 5.51 - 10.16	Updated Date 11/10/2024

Company Size Small-Cap Stock	Market Capitalization 152.89M USD	Price to earnings Ratio -	1Y Target Price -
Dividends yield (FY) -	Basic EPS (TTM) -1.85	Volume (30-day avg) 47219	Beta -
52 Weeks Range 5.51 - 10.16	Updated Date 11/10/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value 158213735	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding 19111600	Shares Floating 546301
Percent Insiders 19.1	Percent Institutions 52.21

Trailing PE -	Forward PE -	Enterprise Value 158213735	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 19111600	Shares Floating 546301
Percent Insiders 19.1	Percent Institutions 52.21

Analyst Ratings

Rating -	Target Price -	Buy -
Strong Buy -	Hold -	Sell -
Strong Sell -

Rating -	Target Price -	Buy -	Strong Buy -
Hold -	Sell -	Strong Sell -

About Actuate Therapeutics, Inc. Common stock

Exchange	NASDAQ	Headquaters	Fort Worth, TX, United States
IPO Launch date	2024-08-13	CEO, President & Director	Mr. Daniel M. Schmitt
Sector	Healthcare	Website	https://actuatetherapeutics.com
Industry	Biotechnology	Full time employees	11
Headquaters	Fort Worth, TX, United States
CEO, President & Director	Mr. Daniel M. Schmitt
Website	https://actuatetherapeutics.com
Website	https://actuatetherapeutics.com
Full time employees	11

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.